Glaxosmithkline Share News (GSK)

GSK to divest 6 percent stake in S.Africa's Aspen

LONDON, Nov 19 (Reuters) - GlaxoSmithKline said on Tuesday it planned to reduce its investment in South African drugmaker Aspen Pharmacare, although it will retain a board seat and significant shareholding. Britain's biggest drugmaker intends to offload around 6 percent of Aspen's issued sh

FTSE 100 movers: Aberdeen retreats from yesterday's big high

Fund manager Aberdeen was firmly in the red, pulling back after a 15 per cent surge on Monday following the announced acquisition of the Scottish Widows Investment Partnership Group from Lloyds, as well a strong increase in annual profits. Numis downgraded the stock to 'hold' this morning, although

GSK to sell down Aspen Pharma stake

GlaxoSmithKline has revealed plans to sell 450m pounds of shares in Africa's largest drug company, Aspen Pharmaceutical. GSK said it wanted to offload around a third of its 19% stake in Johannesburg-listed Aspen, which is currently valued at 122bn rand, equivalent to £7.5bn. The 6% of sold shares

Global drug spending to surpass $1 trillion in 2014 -report

Nov 19 (Reuters) - Global spending on drugs will surpass $1 trillion next year and increase 3 to 6 percent annually over the next five years as both developed and developing nations spend more on medicine, according to a study released on Tuesday. Spending on expensive new specialty drugs f

DIRECTOR DEALINGS: GlaxoSmithKline Manager Sells Shares After Exercising Options

GSK awarded European marketing authorisation for asthma and COPD treatment

Pharmaceutical giant GlaxoSmithKline (GSK) has received European marketing authorisation for Relvar Ellipta, a treatment for asthma and Chronic Obstructive Pulmonary Disease (COPD), which is now licensed across 31 European countries. Darrell Baker, the Head of GSK Global Respiratory Franchise, sai

GSK's asthma drug Relvar approved in Europe

LONDON, Nov 18 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive pulmonary disease (COPD), confirming an endorsement from regulators in September. The medicine, which is inhaled through a palm-s

GlaxoSmithKline Granted Europe Marketing Authorisation For Relvar Ellipta

DIRECTOR DEALINGS: GlaxoSmithKline Executives Allocated Additional American Depositary Shares

Last-line antibiotics losing ability to kill superbugs in EU

* ECDC survey shows rise in carbapenem resistance * Problem most acute in southern Europe * Health experts urge prudent drug use, more research By Ben Hirschler LONDON, Nov 15 (Reuters) - Europe faces a growing threat from superbugs that are resistant to a powerful, last-r

CORRECTED-Merck invests $107 million in China drug plant

(Corrects company name and RIC to Merck KGaA in para 1, deletes reference to Merck in para 6) * China market could by world's second-biggest by 2016 * Healthcare spending forecast to hit $1 trillion by 2020 * Major drug companies investigated on pricing, corruption * Inter

UPDATE 2-Sarepta shares plunge 60 pct after FDA questions drug trial

* FDA questions drug trial design, says approval application premature * FDA suggests company may need to do larger trial * Analysts say there's almost no chance of an early approval * At least three brokerages downgrade stock * Stock drop wipes off $750 mln of Sarepta's m

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares

Broker tips: RBS, Vodafone, GlaxoSmithKline

Analysts at Goldman Sachs have a positive view on the strategy outlined by Royal Bank of Scotland alongside its third-quarter results. However, the group's new target for common Tier-1 equity, of over 12% versus over 10% before, means that there is now reduced upside potential in RBS shares, "towar

Broker snap: Panmure downgrades GSK after heart drug failure

Broker Panmure Gordon downgraded GlaxoSmithKline after its heart drug Darapaldib, 'the great white hope in the pipeline', failed to reach its primary end-point in a late-stage trial. Analyst Savvas Neophytou trimmed his forecasts, mainly assuming a £150m writedown in the fourth quarter even though